Quest PharmaTech Inc: MDA EN
Quest PharmaTech Inc: AUDITED ANNUAL FINANCIAL STATEMENTS EN
Quest PharmaTech Inc: INTERIM MDA AMENDED EN
Quest PharmaTech Inc: INTERIM FINANCIAL STATEMENTSREPORT AMENDED EN
Quest PharmaTech Inc: MDA AMENDED EN
Quest PharmaTech Inc: AUDITED ANNUAL FINANCIAL STATEMENTS AMENDED EN
Quest PharmaTech Brief: Says Quest Has a 42.5% Ownership Interest in OncoQuest; Adds Dividend Income Will Be Used by Quest for General Corporate Purposes
Quest PharmaTech Brief: Received a Cash Dividend Payment From OncoQuest Inc. of Approximately C$685,000
Quest PharmaTech Inc. Says Oregovomab Phase III Clinical Study Fails Futility Analysis
Quest PharmaTech Inc: INTERIM MDA EN
Quest PharmaTech Inc: INTERIM FINANCIAL STATEMENTSREPORT EN
Quest PharmaTech Provides Corporate Update
Quest PharmaTech Announces Results From AGM
Quest PharmaTech Provides Product Development Update
Quest PharmaTech Inc: INTERIM FINANCIAL STATEMENTS/REPORT - ENGLISH
Quest PharmaTech Inc: MD&A - ENGLISH
Quest PharmaTech Inc: AB FORM 13-501F1 (CLASS 1 AND 3B REPORTING ISSUERS - PARTICIPATION FEE)
Quest PharmaTech Inc: AUDITED ANNUAL FINANCIAL STATEMENTS - ENGLISH